Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia (LLC2007SA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00645606
Recruitment Status : Completed
First Posted : March 27, 2008
Last Update Posted : August 1, 2017
Roche Pharma AG
French Innovative Leukemia Organisation
Information provided by (Responsible Party):
University Hospital, Tours